Jim Simons Biotechnology

Renaissance Technologies LLC

$63.4 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
AMLX Amylyx Pharmaceuticals, Inc.	$214M	$1.75 Million 0.0% of portfolio	464,400	Q4 2024 Added 70.86%
MGNX Macrogenics Inc	$77.4M	$1.75 Million 0.0% of portfolio	538,523	Q4 2024 Added 69.12%
INSM Insmed Inc	$10.6B	$1.75 Million 0.0% of portfolio	25,287	Q4 2024 New
ALEC Alector, Inc.	$107M	$1.73 Million 0.0% of portfolio	915,738	Q4 2024 Added 63.02%
KRYS Krystal Biotech, Inc.	$4.72B	$1.71 Million 0.0% of portfolio	10,900	Q4 2024 Reduced 24.31%
GLUE Monte Rosa Therapeutics, Inc.	$238M	$1.71 Million 0.0% of portfolio	245,700	Q4 2024 Added 12.35%
OCGN Ocugen, Inc.	$173M	$1.67 Million 0.0% of portfolio	2,087,632	Q4 2024 New
ZNTL Zentalis Pharmaceuticals, Inc.	$103M	$1.63 Million 0.0% of portfolio	539,345	Q4 2024 Reduced 3.16%
DSGN Design Therapeutics, Inc.	$235M	$1.56 Million 0.0% of portfolio	253,500	Q4 2024 Reduced 7.48%
GOSS Gossamer Bio, Inc.	$110M	$1.54 Million 0.0% of portfolio	1,712,503	Q4 2024 Reduced 1.85%
ELYM Eliem Therapeutics, Inc.	$109M	$1.53 Million 0.0% of portfolio	372,300	Q4 2024 Added 442.71%
TSHA Taysha Gene Therapies, Inc.	$88M	$1.52 Million 0.0% of portfolio	878,448	Q4 2024 New
VERA Vera Therapeutics, Inc.	$720M	$1.51 Million 0.0% of portfolio	35,700	Q4 2024 New
NUVB Nuvation Bio Inc.	$395M	$1.51 Million 0.0% of portfolio	566,800	Q4 2024 Reduced 44.92%
QSI Quantum Si Inc	$152M	$1.47 Million 0.0% of portfolio	544,956	Q4 2024 Added 1,211.38%
URGN Uro Gen Pharma Ltd.	$255M	$1.47 Million 0.0% of portfolio	138,200	Q4 2024 New
ATOS Atossa Therapeutics, Inc.	$86.1M	$1.46 Million 0.0% of portfolio	1,557,632	Q4 2024 Added 18.9%
AUTL Autolus Therapeutics PLC	$151M	$1.45 Million 0.0% of portfolio	618,942	Q4 2024 Added 146.72%
AADI Aadi Bioscience, Inc.	$40.1M	$1.44 Million 0.0% of portfolio	456,022	Q4 2024 Reduced 1.26%
STOK Stoke Therapeutics, Inc.	$284M	$1.42 Million 0.0% of portfolio	129,043	Q4 2024 New
CTMX Cytom X Therapeutics, Inc.	$38.9M	$1.39 Million 0.0% of portfolio	1,346,800	Q4 2024 Added 32.69%
ADPT Adaptive Biotechnologies Corp	$1.1B	$1.38 Million 0.0% of portfolio	229,785	Q4 2024 Added 35.65%
VTYX Ventyx Biosciences, Inc.	$68.4M	$1.37 Million 0.0% of portfolio	624,500	Q4 2024 Added 99.08%
ADAP Adaptimmune Therapeutics PLC	$34.3M	$1.36 Million 0.0% of portfolio	2,526,524	Q4 2024 Added 52.51%
BMEA Biomea Fusion, Inc.	$67.4M	$1.33 Million 0.0% of portfolio	343,732	Q4 2024 Added 317.66%
ARVN Arvinas, Inc.	$404M	$1.32 Million 0.0% of portfolio	68,900	Q4 2024 Reduced 52.29%
THRD Third Harmonic Bio, Inc.	$142M	$1.31 Million 0.0% of portfolio	127,706	Q4 2024 Added 22.02%
HALO Halozyme Therapeutics, Inc.	$8.89B	$1.25 Million 0.0% of portfolio	26,110	Q4 2024 Reduced 89.77%
IPSC Century Therapeutics, Inc.	$30M	$1.21 Million 0.0% of portfolio	1,202,885	Q4 2024 Added 146.39%
PGEN Precigen, Inc.	$331M	$1.2 Million 0.0% of portfolio	1,067,645	Q4 2024 Reduced 33.28%
CSBR Champions Oncology, Inc.	$130M	$1.19 Million 0.0% of portfolio	138,839	Q4 2024 Added 15.71%
ALLO Allogene Therapeutics, Inc.	$223M	$1.18 Million 0.0% of portfolio	554,541	Q4 2024 Reduced 13.62%
INZY Inozyme Pharma, Inc.	$36.9M	$1.17 Million 0.0% of portfolio	421,399	Q4 2024 Added 155.7%
NTLA Intellia Therapeutics, Inc.	$613M	$1.15 Million 0.0% of portfolio	98,700	Q4 2024 New
SPRO Spero Therapeutics, Inc.	$27M	$1.15 Million 0.0% of portfolio	1,105,591	Q4 2024 Added 13.43%
LCTX Lineage Cell Therapeutics, Inc.	$83.2M	$1.14 Million 0.0% of portfolio	2,283,072	Q4 2024 Added 1,058.33%
KRON Kronos Bio, Inc.	$46.6M	$1.11 Million 0.0% of portfolio	1,171,808	Q4 2024 Added 19.69%
CRMD Cor Medix Inc.	$267M	$1.09 Million 0.0% of portfolio	134,000	Q4 2024 New
LIFE A Tyr Pharma Inc	$53.2M	$1.07 Million 0.0% of portfolio	574,455	Q4 2024 Reduced 50.01%
LYEL Lyell Immunopharma, Inc.	$134M	$1.03 Million 0.0% of portfolio	1,612,146	Q4 2024 Added 716.69%
YMAB Y M Abs Therapeutics, Inc.	$210M	$1.03 Million 0.0% of portfolio	131,600	Q4 2024 Added 371.68%
EYPT Eye Point Pharmaceuticals, Inc.	$199M	$1.02 Million 0.0% of portfolio	137,500	Q4 2024 Reduced 26.64%
ALLK Allakos Inc.	$20.3M	$1.02 Million 0.0% of portfolio	844,233	Q4 2024 Added 16.31%
GBIO Generation Bio Co.	$25.4M	$1.02 Million 0.0% of portfolio	962,959	Q4 2024 Added 62.03%
ELEV Elevation Oncology, Inc.	$6.06M	$929,000 0.0% of portfolio	1,603,309	Q4 2024 Reduced 10.23%
OLMA Olema Pharmaceuticals, Inc.	$171M	$917,000 0.0% of portfolio	157,300	Q4 2024 Added 435.03%
ACET Adicet Bio, Inc.	$33.2M	$879,000 0.0% of portfolio	916,500	Q4 2024 Reduced 25.58%
INMB Inmune Bio, Inc.	$134M	$867,000 0.0% of portfolio	185,800	Q4 2024 Added 73.32%
MRSN Mersana Therapeutics, Inc.	$36.9M	$866,000 0.0% of portfolio	606,285	Q4 2024 Added 23.05%
ALDX Aldeyra Therapeutics, Inc.	$389M	$833,000 0.0% of portfolio	167,100	Q4 2024 Added 55.59%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account